Crinetics Pharmaceuticals Inc Stock News

SAN DIEGO, Feb. 09, 2022 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals (Nasdaq: CRNX), a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of novel the

- Phase 1 multiple ascending dose data for CRN04894 and CRN04777 expected in 1Q 2022 - Initiation of patient dosing in a Phase 2 trial of paltusotine in carcinoid syndrome associated with neuroendocrine tumors expected in 2022 - - Initiation of IND-enabling studies for parathyroid receptor type-1 antagonist expected in 2022 - SAN DIEGO, Jan. 12, 2022 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, today announced that Scott Struthers, Ph.D. , founder & CEO of Crinetics, will provide a company update at the 40 th annual J.P. Morgan Healthcare Conference today, Wednesday, January 12 th at 4:30 PM Eastern Time / 1:30 PM Pacific Time. A live audio webcast of Dr. Struthers'' presentation may be accessed on the Events page of the company''s website. During his presentation, Dr. Struthers will discuss Crinetics'' key priorities and anticipated milestones for 2022.

- Phase 1 multiple ascending dose data for CRN04894 and CRN04777 expected in 1Q 2022 –

Zacks Investment Research upgraded shares of Crinetics Pharmaceuticals (NASDAQ:CRNX) from a hold rating to a buy rating in a report issued on Tuesday morning, Zacks.com reports. The firm currently has $28.00 price objective on the stock. According to Zacks, Crinetics Pharmaceuticals Inc is a clinical stage pharmaceutical company. It focuses on the discovery, development and [] The post Zacks Investment Research Upgrades Crinetics Pharmaceuticals (NASDAQ:CRNX) to Buy appeared first on ETF Daily News .

Crinetics Pharmaceuticals (NASDAQ:CRNX) was downgraded by Zacks Investment Research from a buy rating to a hold rating in a research report issued to clients and investors on Friday, Zacks.com reports. According to Zacks, Crinetics Pharmaceuticals Inc is a clinical stage pharmaceutical company. It focuses on the discovery, development and commercialization of novel therapeutics for rare []

Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) has earned an average rating of Buy from the seven ratings firms that are currently covering the company, MarketBeat reports. Seven research analysts have rated the stock with a buy rating. The average 1 year price objective among brokers that have updated their coverage on the stock in the last year []

Crinetics Pharmaceuticals (NASDAQ:CRNX) was downgraded by Zacks Investment Research from a buy rating to a hold rating in a research note issued to investors on Friday, Zacks.com reports. According to Zacks, Crinetics Pharmaceuticals Inc is a clinical stage pharmaceutical company. It focuses on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases []

Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) was down 9% during mid-day trading on Thursday . The stock traded as low as $24.70 and last traded at $24.86. Approximately 11,130 shares traded hands during trading, a decline of 94% from the average daily volume of 190,346 shares. The stock had previously closed at $27.32. Several analysts have issued []

Cubist Systematic Strategies LLC lifted its stake in shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) by 72,141.2% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 12,281 shares of the companys stock after acquiring an additional 12,264 shares during the quarter. [] The post Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Stock Holdings Lifted by Cubist Systematic Strategies LLC appeared first on ETF Daily News .

Zacks Investment Research upgraded shares of Crinetics Pharmaceuticals (NASDAQ:CRNX) from a hold rating to a buy rating in a research note released on Wednesday morning, Zacks.com reports. They currently have $30.00 target price on the stock. According to Zacks, Crinetics Pharmaceuticals Inc is a clinical stage pharmaceutical company. It focuses on the discovery, development and []

Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX)s share price gapped up prior to trading on Wednesday . The stock had previously closed at $25.53, but opened at $26.19. Crinetics Pharmaceuticals shares last traded at $26.74, with a volume of 1,347 shares trading hands. CRNX has been the topic of a number of analyst reports. HC Wainwright raised their []

Shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) have received a consensus rating of Buy from the six ratings firms that are currently covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a hold rating and five have issued a buy rating on the company. The average 12-month price target among brokers []

SAN DIEGO, Nov. 18, 2021 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, announced today that company management will participate in a fireside chat and one-on-one investor meetings at the 4 th Annual Evercore ISI HealthCONx Conference, which is taking place virtually November 30, 2021 through December 2, 2021.

The mean of analysts' price targets for Crinetics Pharmaceuticals, Inc. (CRNX) points to a 45.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong

Co-founded by Crinetics, 5AM Ventures and Frazier Healthcare Partners, the New Company Launches with $30M in Initial Financing Provided by 5AM and Frazier